17 January 2018
News and Views
Links and Services
This week's Journal of the American Medical Association compares doxorubicin plus sorafenib with doxorubicin alone in patients with advanced hepatocellular carcinoma.
In a randomized phase 3 trial, 400 mg of sorafenib twice daily prolonged overall survival of pati
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors